This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Historically, patient recruitment and retention have been pressing issues within the clinical trial space. Eighty-five percent of trials fail to recruit enough patients, while 80% are delayed due to other factors like participant dropouts. These high rates are influenced by financial, emotional, and logistical barriers to participation, such as geographic location and travel-related costs, which prevent patients from enrolling in trials and accessing life-changing medicine.
A non-addictive pain pill faces its definitive test, while study results in ALS, a rare heart disease and lung cancer could have far-reaching implications.
Amplifying the patient voice is essential for the success of clinical trials. Learn why it is crucial for patient engagement, recruitment, and overall trial success, and how it can address challenges such as transportation and financial barriers.
Speaker: Simran Kaur, Co-founder & CEO at Tattva Health Inc.
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
This content is password protected. To view it please enter your password below: Password: The post Current Opportunities and Outcomes in Rare Disease Clinical Trials appeared first on WCG.
While the primary goal of clinical trials is to help identify potential new treatments that improve people's health and save lives, it's the unfortunate truth that the patient experience is often not prioritized. This discrepancy becomes evident in industry findings, highlighting a substantial disparity between the services patients want from pharmaceutical companies compared to what they actually receive.
Explore how GenAI is revolutionising clinical trials by bringing precision and innovation to the development of therapies. Learn how this technology is improving patient outcomes and advancing the field of clinical research.
Explore how GenAI is revolutionising clinical trials by bringing precision and innovation to the development of therapies. Learn how this technology is improving patient outcomes and advancing the field of clinical research.
In this Friday's PCT Grand Rounds, Rui Wang of Harvard Medical School will offer the final session in our special series, Advances in the Design and Analysis of Pragmatic Clinical Trials, with "Methods for Handling Missing Data in Cluster Randomized Trials." The session will be held on Friday, January 5, at 1:00 pm eastern. Wang is an associate professor of population medicine and the director of the Division of Biostatistics in the Department of Population Medicine at Harvard Medical School and
A 57-year-old woman from Wisconsin recently sustained a rather unfortunate injury to her buttock. She had attended the hospital for an MRI ( magnetic resonance imaging) scan and had entered the machine with a concealed firearm. The machine’s powerful magnet caused the gun to discharge.
Medical imaging has revolutionized diagnostics with artificial intelligence (AI) providing the unprecedented accuracy for fast detection and personalized patient care. The year 2023 for India’s medtech industry characterized by resilience, innovation, provided push toward enhancing healthcare accessibility and quality amid global health challenges.
Moonwalk Biosciences, the latest biotech cofounded by the gene editing scientist, joins other startups aiming to alter gene expression without changing DNA.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
The next time you make yourself a berry smoothie, you might want to hold off on the banana. Sure, this fruit is full of potassium and makes a drink deliciously thick and creamy, but according to researchers from the University of California Davis (UCD), there’s something in bananas that might overpower the antioxidants in berries.
The company plans to restructure and will start a new late-stage study testing whether its “off-the-shelf” therapy can boost cure rates when used early on.
A drug commonly used to treat type 2 diabetes could also effectively protect against colorectal cancer (CRC), based on a new analysis by researchers in the US. The drug in question is a class of medications known as glucagon-like peptide-1 receptor agonists – more easily referred to as GLP-1 RAs.
In this issue: Pharma’s efforts to curb Scope 3 emissions, understanding European Pharmaceutical legislation, and looking back at the pharma industry’s performance in 2023.
Amgen had its bid for full approval of the cancer drug Lumakras turned back by the agency, which also issued complete response letters to Zealand Pharma and Merck & Co. in December.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Dharwad District Chemists & Druggists Association (DDCDA) is devising strategies to differentiate their service with improved customer experience. These span attention to details like patient education to manage their medication, ensure fair business practices in pricing and dispensing medicines efficiently among others.
Lykos Therapeutics, formerly known as MAPS Public Benefit Corp., recently submitted its MDMA capsules for FDA approval, following two positive studies.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Navigating regulatory affairs in the biopharma industry requires a skilled talent pool, according to Benjamin James, HR Leader, Asia-Pacific, Cytiva Lifesciences – a global life sciences (biopharma) company. He cited Cytiva’s Global Biopharma Resilience Index (GBRI), which reveals a decline in overall talent pool resilience, with the score dropping from 6.27 in 2021 to 5.
The new program, dubbed LillyDirect, will help patients connect with telehealth providers and deliver medicines like the company’s obesity treatment Zepbound.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
122 
Let's personalize your content